1082051-60-2

Basic information

• Product Name: ethyl 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoate
• Synonyms: ethyl 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoate
• CAS NO: 1082051-60-2
• Molecular Weight: 463.577
• Mol File: 1082051-60-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoate(1082051-60-2)
• EPA Substance Registry System: ethyl 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoate(1082051-60-2)

Safety Data

• Hazardous Substances Data: 1082051-60-2(Hazardous Substances Data)

Upstream product

• 14113-01-0 Ethyl hydrogen suberate 
• 1082051-84-0 7-amino-1,3-dimethyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one 

Downstream Products

• 1082051-61-3 8-(1,3-dimethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-ylamino)-8-oxooctanoic acid 

Relevant articles and documents

Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents

This study concerns the synthesis of new histone deacetylase inhibitors (HDACi) characterized by a 1,4-benzodiazepine ring used as the cap, joined through an amide function or a triple bond as connection units, to a linear alkyl chain bearing the hydroxamate function as Zn2+-chelating group. Biological tests performed in human acute promyelocytic leukemia NB4 cells showed that new hybrids can induce histone H3/H4 acetylation, growth arrest, and also apoptosis. Notably, chiral compounds exhibit stereoselective activity.